Immune Response to Glycated and Oxidized LDL in IDDM Patients With and Without Renal Disease

OBJECTIVE To study autoantibodies to oxidized and glycated LDL in IDDM patients with and without diabetic nephropathy and in nephropathy-related macroangiopathy RESEARCH DESIGN AND METHODS The study included 101 IDDM patients with a long duration of diabetes and 54 healthy subjects. Patients were divided into two groups according to their median urinary albumin excretion rate (AER); the normoalbuminuric group had AER <20 μg/min and the albuminuric group >200 μg/min. The groups were matched for age and BMI, and the two diabetic groups were matched for duration of diabetes and glycemic control. Antibodies against oxidized LDL (using malondialdehyde-modified LDL as the antigen) and against glycated LDL were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS The mean antibody levels against glycated LDL were higher in IDDM patients (0.305 ± 0.399) than in healthy subjects (0.166 ± 0.22 optical density [OD]; P = 0.019), but levels did not differ significantly between normoalbuminuric and albuminuric IDDM patients (0.258 ± 0.354 vs. 0.388 ± 0.459, respectively). Among the three groups, antibody levels to oxidized LDL did not differ. IDDM patients showed an inverse correlation between antibodies to oxidized LDL and HbA1 (r = −0.211, P = 0.04). The antibody levels to glycated and oxidized LDL did not differ among albuminuric IDDM patients with or without clinical macroangiopathy. CONCLUSIONS Antibodies to glycated and oxidized LDL do not seem to associate with diabetic nephropathy or nephropathy-related macroangiopathy.

[1]  L. Niskanen,et al.  Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[2]  M. Taskinen,et al.  Multiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease , 1996, Diabetes.

[3]  G. Bellomo,et al.  Autoantibodies Against Oxidatively Modified Low-Density Lipoproteins in NIDDM , 1995, Diabetes.

[4]  L. Tenkanen,et al.  Antibody against oxidized low-density lipoprotein predicting myocardial infarction. , 1994, Archives of internal medicine.

[5]  M. Kendall,et al.  The oxidation hypothesis of atherosclerosis , 1994, The Lancet.

[6]  A. Bowie,et al.  Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? , 1993, Atherosclerosis.

[7]  M. Brownlee,et al.  Glycation Products and the Pathogenesis of Diabetic Complications , 1992, Diabetes Care.

[8]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[9]  D. Sullivan,et al.  Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. , 1992, Biochemical pharmacology.

[10]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J L Witztum,et al.  Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.